Compounds and methods for therapy and diagosis of lung cancer
AssigneeCorixa Corporation
InventorTONGTONG WANG
Life of this patent
Estimating the term…
Abstract
Compounds and methods for the treatment and diagnosis of lung cancer are provided. The inventive compounds include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of lung cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.
Claims60
An isolated polypeptide comprising at least an immunogenic portion of a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:
- (a) sequences recited in SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224;
- (b) sequences that hybridize to a sequence of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224 under moderately stringent conditions;
- and
- (c) a complement of a sequence of (a) or (b).
An isolated polypeptide comprising a sequence recited in any one of SEQ ID NO:
- 110, 112, 114, 152, 155, 156, 159, 161, 165, 166, 169, 170, 172, 174 and 176.
An isolated polynucleotide encoding at least 15 amino acid residues of a lung tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224 or a complement of any of the foregoing sequences.
An isolated polynucleotide encoding a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224, or a complement of any of the foregoing sequences.
An isolated polynucleotide comprising a sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224.
An isolated polynucleotide comprising a sequence that hybridizes to a sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224 under moderately stringent conditions.
An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a lung-specific protein, the protein comprising an amino acid sequence encoded by a polynucleotide sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224 or a complement of any of the foregoing polynucleotide sequences.
A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antigen-presenting cell that expresses a polypeptide encoded by a polynucleotide recited in any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224, and thereby inhibiting the development of a cancer in the patient.
A method for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a lung-specific protein, wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:
- (i) polynucleotides recited in any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224;
- and
- (ii) complements of the foregoing polynucleotides;
- wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the lung-specific protein from the sample.
A method for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated according to the method of claim 35.
A method for stimulating and/or expanding T cells specific for a lung-specific protein, comprising contacting T cells with at least one component selected from the group consisting of:
- (i) a polypeptide encoded by a polynucleotide comprising a sequence provided in any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224;
- (ii) a polynucleotide encoding a polypeptide of (i);
- and
- (iii) an antigen presenting cell that expresses a polypeptide of (i),
- under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.
A method for inhibiting the development of a cancer in a patient, comprising the steps of:
- (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of:
- (i) a polypeptide encoded by a polynucleotide comprising a sequence of any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224,
- (ii) a polynucleotide encoding a polypeptide of (i);
- or
- (iii) an antigen-presenting cell that expresses a polypeptide of (i);
- such that T cells proliferate;
- and
- (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.
A method for inhibiting the development of a cancer in a patient, comprising the steps of:
- (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from the group consisting of:
- (i) a polypeptide encoded by a polynucleotide comprising a sequence of any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224;
- (ii) a polynucleotide encoding a polypeptide of (i);
- or
- (iii) an antigen-presenting cell that expresses a polypeptide of (i);
- such that T cells proliferate;
- (b) cloning at least one proliferated cell to provide cloned T cells;
- and
- (c) administering to the patient an effective amount of the cloned T cells, and thereby inhibiting the development of a cancer in the patient.
A method for determining the presence or absence of a cancer in a patient, comprising the steps of:
- (a) contacting a biological sample obtained from a patient with a binding agent that binds to a lung-specific protein, wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:
- (i) polynucleotides recited in any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224;
- and
- (ii) complements of the foregoing polynucleotides;
- (b) detecting in the sample an amount of polypeptide that binds to the binding agent;
- and
- (c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.
A method for monitoring the progression of a cancer in a patient, comprising the steps of:
- (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a lung-specific protein, wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence of any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224, or a complement of any of the foregoing polynucleotides;
- (b) detecting in the sample an amount of polypeptide that binds to the binding agent;
- (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time;
- and
- detected in (d) comparing the amount of polypeptide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.
A method for determining the presence or absence of a cancer in a patient, comprising the steps of:
- (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a lung-specific protein, wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence of any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224, or a complement of any of the foregoing polynucleotides;
- (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide;
- and
- (c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.
A method for monitoring the progression of a cancer in a patient, comprising the steps of:
- (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a lung-specific protein,-wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence of any one of SEQ ID NO:
- 1-109, 111, 113, 115-151, 153, 154, 157, 158, 160, 162-164, 167, 168, 171, 173, 175 and 177-224, or a complement of any of the foregoing polynucleotides;
- (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide;
- (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time;
- and
- (d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.
An oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under moderately stringent conditions to a polynucleotide that encodes a lung-specific protein, wherein the protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO:
- 1-3, 6-8, 10-13, 15-27, 29, 30, 32, 34-49, 51, 52, 54, 55, 57-59, 61-69, 71, 73, 74, 77, 78, 80-82, 84, 86-96, 107-109, 111, 113, 125, 127, 128, 129, 131-133, 142, 144, 148-151, 153, 154, 157, 158, 160, 167, 168, 171, 173, 175, 179, 182, 184-186, 188-191, 193, 194, 198-207, 209, 210, 213, 214, 217 and 220-224, or a complement of any of the foregoing polynucleotides.
Dependencies are inferred from the claim text.